356 results on '"Mueller-Tidow, Carsten"'
Search Results
2. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy
3. Epigenetic control over the cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia
4. The remission status of AML patients after allo-HCT is associated with a distinct single-cell bone marrow T-cell signature
5. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study
6. Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
7. Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies
8. Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia
9. Physical biomarkers for human hematopoietic stem and progenitor cells
10. Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia
11. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
12. Reduced proliferation of bone marrow MSC after allogeneic stem cell transplantation is associated with clinical outcome
13. Overlapping features of therapy-related and de novo NPM1-mutated AML
14. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1
15. Deep sequencing in CD34+ cells from peripheral blood enables sensitive detection of measurable residual disease in AML
16. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
17. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
18. An autologous culture model of nodal B-cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
19. Kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic graft-versus-host disease
20. Phagocytosis by stroma confounds coculture studies
21. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
22. Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
23. Lack of antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients at risk of critical COVID-19
24. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison
25. Storage, Utilization, and Disposal of Hematopoietic Stem Cell Products in Patients with Multiple Myeloma
26. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
27. Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
28. Familial Cancer: How to Successfully Recruit Families for Germline Mutations Studies? Multiple Myeloma as an Example
29. Hepatic leukemia factor is a novel leukemic stem cell regulator in DNMT3A, NPM1, and FLT3-ITD triple-mutated AML
30. Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells
31. Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection
32. The Six1 Homeoprotein Stimulates Tumorigenesis by Reactivation of Cyclin A1
33. Specific Protein Redirection as a Transcriptional Therapy Approach for t(8;21) Leukemia
34. Therapy of older persons with acute myeloid leukaemia
35. Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients
36. Increased DNA methylation of Dnmt3b targets impairs leukemogenesis
37. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction
38. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
39. Trabectedin: Supportive care strategies and safety profile
40. Cryopreservation does not alter main characteristics of Good Manufacturing Process–grade human multipotent mesenchymal stromal cells including immunomodulating potential and lack of malignant transformation
41. Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
42. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
43. The Landscape of Small Nucleolar RNA Expression in Multiple Myeloma
44. A phase 2 clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
45. Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM
46. Prognostic Impact of Bcl-2 Depends on Tumor Histology and Expression of MALAT-1 lncRNA in Non–Small-Cell Lung Cancer
47. Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy
48. High‐dose melphalan‐based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia
49. Post-Hybridization Quality Measures for Oligos in Genome-Wide Microarray Experiments
50. New Molecular Therapy Targets in Acute Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.